Advertisement

Antipsychotic Medication-Induced Weight Gain

  • Leon I. Igel
Chapter

Abstract

A 35-year-old man is referred to you by his psychiatrist for assistance with weight management. The patient has a history of class 2 obesity (height 70 in, weight 258 lb, BMI 37 kg/m2) and bipolar disorder managed with olanzapine. The olanzapine was started 1 year ago after SSRIs and SNRIs proved ineffective. While olanzapine has been helpful with respect to mood, the patient has gained 19 lb since initiating therapy. The patient’s psychiatrist is hopeful that, together, you can formulate a plan to address the patient’s weight while maintaining mood stability.

Keywords

Antipsychotic medication Weight gain Bipolar disorder Olanzapine Obesity 

References

  1. 1.
    Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013 Sep 14;382(9896):951–62.PubMedCrossRefGoogle Scholar
  2. 2.
    Simpson GM, Glick ID, Weiden PJ, et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:1837–47.PubMedCrossRefGoogle Scholar
  3. 3.
    Komossa K, Rummel-Kluge C, Hunger H, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009;4:CD006627.Google Scholar
  4. 4.
    Meyer JM, Mao Y, Pikalov A, et al. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia. Int Clin Psychopharmacol. 2015 Nov;30(6):342–50.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Musil R, Obermeier M, Russ P, et al. Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf. 2015 Jan;14(1):73–96.PubMedCrossRefGoogle Scholar
  6. 6.
    Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011;21:517–35.PubMedCrossRefGoogle Scholar
  7. 7.
    Hasnain M, Vieweg WV, Hollett B. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. Postgrad Med. 2012 Jul;124(4):154–67.PubMedCrossRefGoogle Scholar
  8. 8.
    Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–23.PubMedCrossRefGoogle Scholar
  9. 9.
    Fiedorowicz JG, Miller DD, Bishop JR, et al. Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers. Curr Psychiatr Rev. 2012;8(1):25–36.CrossRefGoogle Scholar
  10. 10.
    Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62(suppl 7):22–31.PubMedGoogle Scholar
  11. 11.
    He M, Deng C, Huang XF. The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain. CNS Drugs. 2013;27(6):423–34.PubMedCrossRefGoogle Scholar
  12. 12.
    Ratliff JC, Barber JA, Palmese LB, et al. Association of prescription H1 antihistamine use with obesity: results from the National Health and Nutrition Examination Survey. Obesity (Silver Spring). 2010;18:2398–400.CrossRefGoogle Scholar
  13. 13.
    Himmerich H, Minkwitz J, Kirkby KC. Weight gain and metabolic changes during treatment with antipsychotics and antidepressants. Endocr Metab Immune Disord Drug Targets. 2015;15(4):252–60.PubMedCrossRefGoogle Scholar
  14. 14.
    Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand. 1999;100(1):3–16.PubMedCrossRefGoogle Scholar
  15. 15.
    Domecq JP, Prutsky G, Leppin A, et al. Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(2):363–70.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Hasnain M, Vieweg WVR, Fredrickson SK. Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions—ProQuest. CNS Drugs. 2010;24(3):193–206.PubMedCrossRefGoogle Scholar
  17. 17.
    Verrotti A, D’Egidio C, Mohn A, et al. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev. 2011;12:e32–43.PubMedCrossRefGoogle Scholar
  18. 18.
    DeToledo JC, Toledo C, DeCerce J, et al. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit. 1997;19:394–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Gaspari CN, Guerreiro CA. Modification in body weight associated with antiepileptic drugs. Arq Neuropsiquiatr. 2010;68:277–81.PubMedCrossRefGoogle Scholar
  20. 20.
    Ben-Menachem E. Weight issues for people with epilepsy – a review. Epilepsia. 2007;48(Suppl 9):42–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Antel J, Hebebrand J. Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. Handb Exp Pharmacol. 2012;209:433–66.CrossRefGoogle Scholar
  22. 22.
    Igel LI, Sinha A, Saunders KH, Apovian CM, Vojta D, Aronne LJ. Metformin: an old therapy that deserves a new indication for the treatment of obesity. Curr Atheroscler Rep. 2016;18(4):16.PubMedCrossRefGoogle Scholar
  23. 23.
    Jesus C, Jesus I, Agius M. A review of the evidence for the use of metformin in the treatment of metabolic syndrome caused by antipsychotics. Psychiatr Danub. 2015;27(Suppl 1):S489–91.PubMedGoogle Scholar
  24. 24.
    Wu R-R, Zhao J-P, Guo X-F, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry. 2008;165(3):352–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Wu R-R, Zhao J-P, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008;299(2):185–93.PubMedCrossRefGoogle Scholar
  26. 26.
    Jarskog LF, Hamer RM, Catellier DJ, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry. 2013;170(9):1032–40.PubMedCrossRefGoogle Scholar
  27. 27.
    Björkhem-Bergman L, Asplund AB, Lindh JD. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. J Psychopharmacol. 2011;25(3):299–305.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Comprehensive Weight Control Center, Division of Endocrinology, Diabetes and MetabolismWeill Cornell Medical CollegeNew YorkUSA

Personalised recommendations